Research Article
Dopaminergic Modulation of Medial Prefrontal Cortex Deactivation in Parkinson Depression
Table 1
Demographic and clinical data (on PD medication).
| | Nondepressed Parkinson’s patients ; (SD) | Depressed Parkinson’s patients ; (SD) | value |
| Age y, mean (SD) | 68.4 (8.2) | 55.2 (7.0) | 0.0002 | Education | 16.0 (3.1) | 15.6 (2.3) | NS | Men/women | 11/7 | 7/3 | NS | Months since diagnosis | 55.7 (39.9) | 43.6 (44.0) | NS | DRS-scaled | 11.0 (2.5) | 12.0 (2.5) | NS | NART-R-FSIQ | 107.5 (7.8) | 99.1 (11.8) | 0.0321 | GDS-15 | 1.9 (1.9) | 6.2 (3.4) | 0.0002 | Hamilton Depression Scale | 4.6 (3.7) | 15.0 (4.6) | <0.0001 | UPDRS-Motor | 16.6 (6.3) | 15.0 (6.2) | NS | UPDRS-Tremor | 1.1 (1.7) | 0.9 (1.2) | NS | Schwab-England ADL | 89.2 (11.5) | 84.0 (13.5) | NS | Levodopa equivalent daily dose | 513.1 (377.7) | 525.0 (430.9) | NS | % on DA agonists | 61.1 | 60.0 | NS |
|
|
Note: DRS: Mattis Dementia Rating Scale. NART-R-FSIQ: National Adult Reading Test-Revised, Estimated Full-Scale IQ. GDS-15: Geriatric Depression Scale-15-Item Version. UPDRS: Unified Parkinson’s Disease Rating Scale. -test. test.
|